Caffeine, Coffee and the Heart: AHA 2026 Statement
What can a manufacturer say on the EU label?

On 20 July 2026, Circulation published the AHA scientific statement “Caffeine and Cardiovascular Disease” (doi: 10.1161/CIR.0000000000001454). The writing group was chaired by Prof. Gregory M. Marcus, MD, MAS, FAHA (UCSF). The document summarises current knowledge on the effects of caffeine and coffee on the cardiovascular system. From the perspective of an EU food manufacturer, however, the critical question is not what science says — but what the law permits on the label.

What the AHA statement says: key findings

The statement is based on a review of dozens of epidemiological studies, several randomised controlled trials, and mechanistic data. Core conclusions:

• Up to 400 mg caffeine per day is a toxicological safety limit for most healthy adults, not a universal recommendation for cups of coffee; caffeine content varies substantially.
• Moderate coffee consumption is associated in observational studies with lower risk of coronary artery disease, stroke, heart failure, and type 2 diabetes.
• The DECAF trial is one of the intervention studies discussed in relation to atrial fibrillation; its findings should not be presented as general proof that coffee prevents recurrence.
• Findings about coffee quantity and heart failure do not establish a universal threshold; risk depends on the population, preparation method, and individual response.
• Energy drinks and caffeine shots should not be treated as equivalent to coffee — case reports suggest arrhythmia and hypertension risks.
• Most data is observational — it does not prove causation.
• Benefits may derive not from caffeine itself, but from other coffee compounds (antioxidants, polyphenols, anti-inflammatory substances).
• Individual response varies due to genetics (CYP1A2 metabolism), habitual intake, age, and comorbidities.

EFSA caffeine safety opinion — what it says and what it does not

In 2015, the EFSA NDA Panel issued the “Scientific Opinion on the safety of caffeine” (EFSA Journal 2015;13(5):4102). Its scope is strictly limited to toxicological safety:

• Up to 400 mg/day — safe for non-pregnant adults
• Up to 200 mg/day — safe for pregnant women
• Single doses up to 200 mg — no safety concerns

Critical caveat: the EFSA opinion assesses safety only. It does not assess health benefits of caffeine. It provides no basis for any health claims. It says nothing about heart protection, diabetes risk reduction, or vascular health improvement. It is a toxicological opinion, not a health recommendation.

Status of caffeine health claims in the EU

Important correction: there are currently no authorised health claims for caffeine. Four claims concerning increased alertness, attention and endurance received positive EFSA opinions, but were never authorised or entered into the applicable EU list. They must not be presented as claims permitted under Regulation 432/2012.

The figures 75 mg per serving and 3 mg/kg body weight one hour before exercise were conditions in a rejected, non-operative proposal. They are not current conditions for a legal caffeine claim.

There are no authorised claims concerning: heart protection, reduced stroke risk, reduced diabetes risk, improved vascular health, reduced heart-failure risk, or increased alertness, attention or endurance.

Why a manufacturer cannot use the AHA statement on the European market

The EU legal system rests on two pillars that together create an insurmountable barrier:

• Art. 10(1) of Regulation 1924/2006: only authorised health claims that are listed in the EU register may be used.
• Art. 7(3) of Regulation 1169/2011: food information shall not attribute disease prevention or treatment properties to food.

In practice this means:

• “Coffee protects the heart” on packaging = illegal health claim
• “Reduces diabetes risk” in marketing materials = breach of law
• Citing the AHA statement as justification = insufficient; a scientific publication does not replace authorisation and entry in the EU register
• Accurate general information about a scientific publication requires context-specific assessment and must not imply a specific health benefit for caffeine or coffee.

The CJEU C-363/19 nuance

In case C-363/19, the Court of Justice clarified that a general, non-specific reference to health or well-being in commercial communication must be accompanied by a specific authorised health claim from the EU lists. The judgment did not authorise any caffeine claim and cannot turn a positive EFSA opinion or the AHA statement into an authorised claim. Since there is currently no authorised caffeine health claim, adding a general phrase such as “good for the heart” to an unauthorised caffeine message does not cure the legal problem.

flowchart TD
    A[Manufacturer wants to use\nAHA findings on\nEU product label] --> B{Type of\ncommunication?}
    B -->|Accurate general information\nwithout health suggestion| D[Permissible only after\ncontext review; no promise\nof a health benefit]
    B -->|Health claim\nArt. 13 or Art. 14| C{Is caffeine claim\nauthorised in the\nEU register?}
    C -->|No - none currently| F[ILLEGAL\nArt. 10 Reg. 1924/2006]
    C -->|Yes - verify current entry| G[Use only the exact\nwording and conditions\nof that entry]
    D --> H{Does the message imply\na specific health benefit?}
    H -->|Yes| F
    H -->|No| I[General information\nwithout a health claim]
    style F fill:#7f1d1d,stroke:#f87171,color:#fecaca
    style G fill:#064e3b,stroke:#10b981,color:#d1fae5
    style D fill:#1e3a8a,stroke:#38bdf8,color:#dbeafe
    style I fill:#064e3b,stroke:#10b981,color:#d1fae5

EFSA opinion vs. AHA statement — comparing their scopes

These two documents are often confused or treated interchangeably. They differ fundamentally in scope, purpose, and legal consequences:

flowchart LR
    subgraph EFSA["EFSA OPINION 2015 (4102)"]
        direction TB
        E1[Scope: toxicological\nsafety of caffeine]
        E2[Says: safe intake limits\n400 mg/day for adults]
        E3[Does NOT say: anything\nabout health benefits]
        E4[Legal effect: no basis\nfor health claims]
        E5[Four positive EFSA opinions\nwere never authorised]
    end
    subgraph AHA["AHA STATEMENT 2026"]
        direction TB
        A1[Scope: review of\ncoffee/caffeine and CVD\nassociations]
        A2[Says: correlation with lower\nrisk of coronary disease\nstroke and heart failure]
        A3[Does NOT say: does not\nprove causation]
        A4[Legal effect: none\nunder EU law]
    end
    EFSA -.->|Neither document authorises\nclaims about caffeine or\nthe heart in the EU| AHA
    style E4 fill:#1e293b,stroke:#f59e0b,color:#fbbf24
    style A4 fill:#1e293b,stroke:#f59e0b,color:#fbbf24

Practical consequences for manufacturers and importers

The AHA statement changes the scientific picture but does not change the law. Practical implications:

• Caffeine supplement manufacturers — cannot present AHA findings as health claims in consumer-facing EU communications. Accurate general information requires context-specific assessment and must not imply an unauthorised benefit.
• Coffee producers — cannot currently use any authorised health claim for caffeine. The 75 mg and 3 mg/kg figures came from an old proposal and are not conditions for a legal claim.
• Importing US products with cardioprotective claims — placing on the EU market a product whose label suggests heart protection constitutes a labelling law violation.
• Energy drinks — a separate risk category. The EU already requires the “High caffeine content” warning; the AHA statement further underscores arrhythmia risk at high doses.

Energy drinks — a separate risk

The AHA statement explicitly distinguishes coffee from energy drinks and caffeine shots. Key warnings:

• Case reports of cardiac arrhythmias after energy drink consumption
• High caffeine concentrations combined with other stimulants may have synergistic effects
• Lack of long-term safety data for this category

In the EU, energy drinks are subject to labelling requirements under Regulation 1169/2011 (mandatory warning: “High caffeine content. Not recommended for children or pregnant or breast-feeding women”), but further sales restrictions remain at the discretion of individual Member States.

Conclusions

The July 2026 AHA statement is a rigorous summary of the state of science — and for private individuals it may provide reassurance about continuing to drink coffee. For a food or supplement manufacturer operating in the EU, however, the document changes nothing in the legal sphere. The gap between scientific observation and regulatory entitlement is deliberate: it protects consumers from the transformation of statistical correlations into marketing promises.

A manufacturer wishing to communicate health properties of caffeine legally in the EU cannot rely on a positive EFSA opinion or the AHA statement. Authorisation by the European Commission after EFSA assessment would be required; as of today, no such caffeine claim exists. The 75 mg and 3 mg/kg figures belong only to a rejected, non-operative proposal, not to current marketing conditions.

Disclaimer: Tomasz Krawczyk — legal counsel specialising in EU and Polish food law and dietary supplements. supplemental.pl · foodlaw.ai. This material is for general information only and reflects the status as of July 2026; it does not constitute legal advice in any individual matter.